SurModics to Webcast Third Quarter 2012 Earnings Conference Call on August 1st

<0> SurModics, Inc.Timothy J. Arens, Vice President of Finance and interim Chief Financial Officer952-500-7000 </0>

SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, announced today that it will host a live webcast of its third quarter 2012 conference call on Wednesday, August 1, at 4:00 p.m. CT. The Company will issue an earnings news release after the market closes that afternoon.

Gary Maharaj, chief executive officer, and Tim Arens, vice president of finance and interim chief financial officer, will recap the third quarter 2012 financial results and accomplishments. To access the webcast, go to the investor relations portion of the Company's website at the day of the conference call and click on the webcast icon.

An audio replay will be available beginning at 7:00 p.m. CT on Wednesday, August 1, until 7:00 p.m. CT on Wednesday, August 8 and can be accessed by dialing 800-406-7325 and entering conference call ID passcode 4556791. In addition, the conference call audio will be archived on the Company's website following the call.

SurModics' mission is to exceed our customers' expectations and enhance the well-being of patients by providing the world's foremost, innovative surface modification technologies and diagnostic chemical components. The Company partners with the world's leading and emerging medical device, diagnostic and life science companies to develop and commercialize innovative products designed to improve patient diagnosis and treatment. Core offerings include surface modification coating technologies that impart lubricity, prohealing, and biocompatibility capabilities; and components for diagnostic test kits and microarrays. SurModics is headquartered in Eden Prairie, Minnesota. For more information about the Company, visit . The content of SurModics' website is not part of this press release or part of any filings that the Company makes with the SEC.

Suggested Articles

The data was highly anticipated, especially since the two partners continued testing after the compound missed its endpoints in phase 2 studies.

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.

Vertex is keeping mum on exact details but, as with the rest of its biopharma peers, is seeing trial disruption due to the COVID-19 pandemic.